Cancer/Oncology Drug Market
By Drug (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, and Others),
By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy),
By Cancer (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Others)
By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa):
Global Analysis and Forecast 2022-2032.
Global cancer/oncology drug market showcased a revenue of USD 172.3 billion in 2021 and is projected to witness a compounded annual growth rate (CAGR) of more than 7.38 % over the forecast period of 2022-2032.
Russia-Ukraine War Impact
Market Scope
About the Market
Impact of COVID-19
Global Economic Slowdown
Market Dynamics
Driver
Restrain
Opportunity
Recent Developments
Synopsis
How is this report helpful
FAQ's
Report Coverage
Related Reports
Cancer is the body's uncontrolled proliferation of abnormal cells. Cancer may develop when the body's natural regulatory mechanism fails. Oncology drugs are prescription medications that are used to treat cancer. Strong technological advancements, rising awareness of the high cancer death rates, an increase in the prevalence of different cancer types, and a greater need for better R&D activities in cancer therapy are drivers of expanding product demand.
Patients with malignancies of the lung, bone, and other organs frequently use painkillers, including acetaminophen, morphine, and fentanyl, as well as NSAIDs (nonsteroidal anti-inflammatory medications). Owing to a rise in the number of cancer diagnoses, there has been a huge increase in the amount of budget allocation on cancer-fighting drugs. Owing to this, increasing the number of cancer cases is anticipated to drive the market's growth. Despite the vast amount of research and quick advancements shown over the previous ten years, cancer still claims millions of lives each year. With respect to the data published by the American Cancer Society (ACS), 1.9 million new cancer cases will be diagnosed in Americans in 2022, and 609,360 people will die from cancer. Owing to this, demand for generic cancer drugs will increase quickly.
To satisfy the requirements of those impacted in emerging economies, manufacturers are working on new initiatives that focus on diseases for which no oncology medications are available for a range of age groups. This would support the businesses' long-term ability to continue selling oncology medications. For instance, in June 2022, an international strategic partnership and licensing agreement between Astellas Pharma Inc. and Sutro Biopharma Inc. was publicly disclosed. Its goal is to find and create new immunostimulatory antibody-drug conjugates (iADCs). The partnership takes use of the distinct anti-cancer potential of iADCs as a novel modality, made possible by Sutro's capacity to design complex conjugated antibodies and Astellas' extensive experience in worldwide oncology R&D.
Impact of the Russia-Ukraine War on the Cancer/Oncology Drug Market
The conflict between Russia and Ukraine has significantly impacted international trade. Due to the halting of clinical trials and therapeutic procedures in Ukraine, there is a decreased demand for oncology drugs and other oncology cancer supplies used in pharmaceutical research and treatment. There would be a serious lack of oncology pharmaceuticals at several research and treatment centers as a result of the trade restrictions imposed on Russia. The suspension of commercial operations in these two countries, which has been bolstered by many companies' avoidance of doing business in Russia, has hampered the growth of the cancer/ oncology drug market.
Cancer/Oncology Drug: Market Scope
Cancer/oncology drug market is divided into four segments: drug, therapy, and cancer type. Furthermore, these segments are subdivided into respective categories and cross-referenced to North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa for regional analysis. The drug segment is further categorized into cytotoxic drugs, targeted drugs, hormonal drugs, and others. The therapy segment is segregated into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. Lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and others bifurcate the cancer type segment of the Cancer/Oncology Drug market. Each of these segments is further classified into regions: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The historical dataset of 2017-2021 is provided in the report, whereas the forecast period of 2022-2032 is offered.
Targeted Drugs will capture the highest market share within the drug segment.
Targeted drugs are predicted to accelerate market expansion. Since the majority of the medications are accessible in capsule and tablet form and are an effective method of delivery, the segment is anticipated to accelerate the global market for targeted cancer therapies. Furthermore, targeted therapy can have fewer adverse effects than other cancer therapies and less impact on normal cells. Targeted drugs are available in a variety of forms. Depending on their modes of operation, these are categorized together. Monoclonal antibodies, medications that prevent the formation of cancer blood vessels, cancer growth inhibitors, and PARP inhibitors are some of these categories. Additionally, cancer research centers, and medical testing, drug development have been established in several regions. This has greatly boosted the market for targeted cancer treatments over the past few years.
The targeted therapy segment will witness the highest growth rate between 2022-2032
Targeted therapy is increasingly being used as a potential cancer treatment. It uses pharmaceutical drugs and other products to detect cancer cells, inhibits their growth, and prevent the disease from spreading to other body parts. Hormone treatments, signal transduction inhibitors, and apoptosis inducers are some of the additional approved variations of this targeted therapy. Thus, Targeted therapy holds the key to extending lifespan while minimizing the negative consequences of cancer treatment. Patients who received matched targeted therapy had significantly improved overall survival (OS) and progression-free survival compared to those who did not (PFS). Additionally, the market is growing as a result of the large investments made by pharmaceutical companies in researching and developing biologically targeted medications. For instance, in December 2022, according to Novartis, the European Commission (EC) authorized the targeted radioligand therapy known as Pluvicto. Pluvicto fills a large unmet need by becoming the first PSMA-targeted radioligand therapy to show therapeutic benefit in mCRPC patients before commencing taxane-based chemotherapy.
The Breast Cancer Type segment will capture the highest market share in the coming years.
The most prevalent types of cancer in men are lung and prostate cancer, whereas breast cancer is one of the most common types in women. The increase in instances of these malignancies is fueling cancer drugs. Furthermore, Manufacturers are increasingly working together or partnering with other businesses to exchange resources, technology, and product knowledge and grow their businesses. For instance, In march 2019, An international development and commercialization collaboration agreement between AstraZeneca and Daiichi Sankyo Company, Limited is focused on the development and commercialization of trastuzumab deruxtecan (DS-8201), a patented antibody-drug conjugate (ADC) and potential innovative targeted medicine for the breast cancer treatment.
Asia Pacific to capture the highest market share in Cancer/Oncology Drug Market
Asia Pacific region is anticipated to have tremendous growth as a result of increased local manufacturing and population. Additionally, the oncology/cancer drug market is expanding as a result of increased awareness of cancer treatments in the Asia Pacific region. Other factors include improved healthcare infrastructure and cost-effective treatment options; the Asia Pacific is predicted to experience profitable growth over the forecast period. Furthermore, China has also been identified as one of the main centers for generic pharmaceutical manufacture due to the low manufacturing costs associated with these items, which further enhances the demand for these products throughout the Asia Pacific Oncology Drugs Market.
Impact of COVID-19 on the Cancer/Oncology Drug Industry
Due to more people being treated for the coronavirus than for cancer, the COVID-19 outbreak had a negative impact on the expansion of the market for oncology drugs. Lockdowns and limitations brought on by the pandemic have delayed and affected global supply networks and drug production processes. The market growth for oncology medications was hampered by the risk of coronavirus infection during the pandemic. Oncology practices adopted certain precautionary measures, such as limiting the number of patients in outpatient clinics, scaling back on unnecessary, and releasing patients from inpatient care. Furthermore, surgery delays due to the unexpected rise of COVID-19 cases worldwide. Additionally, those who had chronic diseases, including lung and blood cancer, faced the risk of developing life-threatening conditions.
Cancer/Oncology Drug: Market Dynamics
The market dynamics section of the report covers a depth analysis of drivers and restraints opportunities impacting cancer/oncology drug market. The report also encompasses major market strategies practiced by the industry, followed by patent analysis, product analysis, competitive benchmarking of companies, PORTER and PESTLE analysis of the Cancer/Oncology Drug industry, pricing analysis, and geographic competitiveness to provide a detailed understanding. The major players operating the market are AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC), Merck & Co. Inc., Novartis AG, Pfizer Inc. These companies cumulatively hold the majority of the cancer/oncology drug market share and actively undergoes strategic development, such as new product launch, merger, collaboration, business expansion, acquisition, and long-term contracts to ensure market penetration. These companies also largely focus on research and development to gain technological competitiveness in the market. A detailed analysis of these companies is offered in the report.
Driver: Increasing prevalence of cancer
The increased incidence of cancer is the main factor influencing market expansion. Therefore, the growing incidence of kinds of cancer has a positive effect on market growth. Owing to this, new product approvals and medicine launch support market expansion. In addition, the market is developing due to pharmaceutical companies' expanding R&D efforts. One of the main causes of cancer worldwide is tobacco. Cancer of the larynx, throat, kidney, colon, rectal, esophagus, and mouth is also caused by it. According to the WHO, more than 8 million people are deceased as a result of tobacco usage every year. More than 7 million of those fatalities are due to direct tobacco use, whereas around 1.2 million are due to secondhand smoke exposure for non-smokers. The 1.3 billion tobacco users globally, or more than 80% of them, live in low- and middle-income countries. For instance, In the United States, there will be 609,360 cancer deaths and an estimated 1.9 million newly diagnosed cancer cases in 2022.
Restrain: Adverse effects, high cost of the drug.
Rising cancer drug prices adversely affect global access and treatment results, with low- and middle-income countries suffering the most. The medications required for targeted therapy treatments are frequently unaffordable. Therefore, greater therapeutic costs are anticipated to hinder market expansion. In addition, the market growth is constrained by the side effects of cancer/oncology medications. Cancer medications destroy cancer cells. Additionally, these medications harm healthy cells. For the patients, this has several negative impacts. Some side effects include intestinal issues, neuropathies, bone marrow suppression, skin issues, hair loss, and weariness. Therefore, these side effects of cancer medications hamper the market growth.
Opportunity: A surge in R&D spending, mergers, and acquisition
Pharmaceutical businesses invest a fund each year in research and development, particularly in the field of oncology. In 2019, the pharmaceutical industry invested $83 billion in R&D. These costs were incurred for a range of activities, such as creating and testing new medications, incremental improvements like product expansions, and clinical testing for marketing or safety monitoring. Recently approved medications frequently belong to the category of "specialty drugs." Specialized handling or patient monitoring may be necessary for specialty medications, which usually treat chronic illnesses.
Furthermore, the pharmaceutical sector has relied on market expansion through a number of merger and acquisition agreements. To treat rare cancers, GSK has reached a $1.9 billion deal to acquire Sierra Oncology. A rare blood cancer called myelofibrosis develops in major bone marrow scarring and severe anemia. Nearly all patients will eventually develop anemia, with about 40% of patients already having it at the time of diagnosis.
Oncology/ Cancer Drug Market: Recent Developments
- In September 2022, Positive results with NXP800 in a preclinical xenograft model of ARID1a-mutated gastric cancer were reported by Nuvectis Pharma, Inc. Over 28 days, tumor volumes in mice in each group received either vehicle or NXP800 treatment, and they were measured. In comparison to the control, treatment with NX800 caused a tumor to retreat and significantly inhibited tumor growth.
- In May 2021, Under the brand name "Ujvira," Zydus Cadila introduced Trastuzumab Emtansine, the first Antibodies Drug Conjugate (ADC) biosimilar and a huge successful medicine for treating both Early and Advanced HER2 Positive Breast Cancer.
- In August 2021, Bristol Myers Squibb received conditional marketing authorization from the European Commission to use Abecma (idecabtagene vicleucel) to cure elderly patients with relapse and severe multiple myeloma. Targeting the B-cell maturation antigen, it is a novel CAR T-cell immunotherapy (BCMA).
- In October 2021, according to a U.S. Food and Drug Administration (FDA) approved test, atezolizumab is allowed for use as an adjuvant therapy after resection and platinum-based chemotherapy in patients with advanced II to the stage.
Oncology/ Cancer Drug Market: Synopsis
The oncology/ cancer drug market study offers revenue and growth data sets of segments provided at the global, regional, and country levels. The report offers the historical data set for 2017-2021 and the forecast period of 2022-2032. For the purpose of analysis, Quadrant Market Insights (QMI) has segregated the Oncology/ Cancer Drug Market into four major segments as follows:
By Drug
- Cytotoxic Drugs
- Targeted Drugs
- Hormonal Drugs
- Others
By Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
By Cancer Type
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer
- Kidney Cancer
- Bladder Cancer
- Others
The regional analysis of Cancer/Oncology Drug Market is as follows:
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Russia
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Chille
Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Israel
Key players operating in Cancer/Oncology Drug industry are:
- AbbVie Inc
- Amgen
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd.
- Johnson & Johnson (Janssen Global Services, LLC)
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
Cancer/Oncology Drug Market: Who Should Purchase, and How It Will Help Readers
- The report is best suited for top-level decision-makers, individuals who are supposed to take a leadership role or require market research to start a business, independent researchers, research institutes, and anyone who wishes to gain detailed strategic insights into the cancer/oncology drug market.
- This report provides a qualitative and quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer/oncology drug market analysis from 2017 to 2032 to identify the prevailing market opportunities.
- Market research and information related to key drivers, restraints, and opportunities are offered.
- Porter's five forces and PESTLE analysis highlight the potency of buyers and suppliers to enable stakeholders' market profit-oriented business decisions and strengthen their supplier-buyer network.
- An in-depth analysis of the cancer/oncology drug market segmentation assists in determining the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes an analysis of the regional and global cancer/oncology drug industry trends, key players, market segments, application areas, and market growth strategies.
- The report offers insights from primary interviews and CXOs of major industry players. It also offers a comprehensive contact and event repository to ensure future collaborations among industry stakeholders.
Cancer/Oncology Drug Market: Frequently Asked Questions (FAQ)
Q: How big is the cancer/oncology drug market?
A: The global cancer/oncology drug market showcased a revenue of USD 172.3 billion in 2021 and is projected to witness a compounded annual growth rate (CAGR) of more than 7.38% over the forecast period of 2022-2032.
Q: Does the report have several cancer/oncology drug bifurcated by segments and regions?
A: The report offers a total number of cancer/oncology drug , further bifurcated into segments and regions. Please refer to the TOC page for more information.
Q: What are the major trends in the cancer/oncology drug market?
A: The rise in awareness from the consumer end about various usage and benefits of cancer/oncology drug, followed by increasing research and development by major industry players across the globe, are major trends expected to shape the market opportunities over the coming years.
Q: How can I get the sample Report on the cancer/oncology drug market?
A: The cancer/oncology drug market report sample can be obtained on demand from the website. Also, 24*7 chat support and direct call services are provided to procure the sample report
Q: Is it possible to purchase a specific or customized report as per my needs
A: Yes, it is possible to purchase a specific part of the report or edit the scope of the report at your convenience. Feel free to drop us the mail/talk to our customer support or schedule a conversation to procure a customized report.
Report Coverage
- Drug
- Therapy
- Cancer Type
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
- Increasing prevalence and diagnosis of cancer
- Technological advancement in pharma industry and growing investment towards cancer drug research and development
- Regulatory support and financial benefits offered to research centres and patients suffering from such disease
- Development of more effective diagnosis tools and establishment of cancer care centres
- Adoption of targeted therapies and Immunotherapies
- High cost of research and development followed by intense competition
- Possibility of adverse effect through inject of cancer drugs
AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC), Merck & Co. Inc., Novartis AG, Pfizer Inc.
1. Introduction
1.1 Report Description
1.1.1 Definition
1.1.2 Abbreviations
1.2 Key Market Segments
1.3 Benefits to Stakeholders
1.4 Research Methodology
1.4.1 Market Scoping
1.4.1.1 Problem Identification
1.4.1.2 Defining the Market
1.4.2 Market Estimation
1.4.2.1 Data Mining
1.4.2.2 Product Analysis
1.4.2.3 Application Analysis
1.4.2.4 Market Engineering and Forecasting
1.4.2.4.1 Bottom-up Demand Side
1.4.2.4.2 Bottom-up Supply side
1.4.3 Market Authentication
1.4.3.1 Data Triangulation
1.4.3.1.1 Top-down Supply Side
1.4.3.1.2 Top-down Demand Side
1.4.3.1.3 Data Triangulation
1.4.3.2 Primary Insights and Industry feedback
1.4.4 Report Writing
2. Executive Summary
2.1 Market Snapshot
2.2 Primary Insights
3. Market Overview
3.1 Market Segment and Scope
3.2 Top Investment Pockets
3.3 Key Strategic Initiatives
3.4 Cancer/Oncology Drug Market Industry Ecosystem
3.5 Market Evolution
3.6 Patent Analysis
3.7 Technology Landscape
3.8 Regulatory Infrastructure
3.9 Porter’s Analysis
3.9.1 Bargaining Power of Buyer
3.9.2 Bargaining Power of Supplier
3.9.3 Threat of New Entrants
3.9.4 Threat of Substitutes
3.9.5 Industry Rivalry
3.10 PESTLE Analysis
3.11 Market Dynamics
3.11.1 Drivers
3.11.2 Restrains
3.11.3 Opportunities
3.12 Impact of COVID-19 on Cancer/Oncology Drug Market
3.13 Russia-Ukraine War Impact on Cancer/Oncology Drug Market
3.14 Growth Share Matrix
3.15 Cancer/Oncology Drug Market Quadrant
4. Cancer/Oncology Drug Market, By Drug
4.1 Major Impacting Factors, By Drug
4.1.1 Key Market Trends and Growth Factors
4.1.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
4.1.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
4.2 Cytotoxic Drugs
4.2.1 Key Market Trends and Growth Factors
4.2.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
4.2.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
4.3 Targeted Drugs
4.3.1 Key Market Trends and Growth Factors
4.3.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
4.3.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
4.4 Hormonal Drugs
4.4.1 Key Market Trends and Growth Factors
4.4.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
4.4.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
4.5 Others
4.5.1 Key Market Trends and Growth Factors
4.5.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
4.5.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
5. Cancer/Oncology Drug Market, By Therapy
5.1 Major Impacting Factors, By Therapy
5.1.1 Key Market Trends and Growth Factors
5.1.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
5.1.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
5.2 Chemotherapy
5.2.1 Key Market Trends and Growth Factors
5.2.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
5.2.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
5.3 Targeted Therapy
5.3.1 Key Market Trends and Growth Factors
5.3.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
5.3.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
5.4 Immunotherapy
5.4.1 Key Market Trends and Growth Factors
5.4.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
5.4.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
5.5 Hormonal Therapy
5.5.1 Key Market Trends and Growth Factors
5.5.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
5.5.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6. Cancer/Oncology Drug Market, By Cancer Type
6.1 Major Impacting Factors, By Cancer Type
6.1.1 Key Market Trends and Growth Factors
6.1.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.1.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.2 Lung Cancer
6.2.1 Key Market Trends and Growth Factors
6.2.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.2.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.3 Stomach Cancer
6.3.1 Key Market Trends and Growth Factors
6.3.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.3.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.4 Colorectal Cancer
6.4.1 Key Market Trends and Growth Factors
6.4.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.4.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.5 Breast Cancer
6.5.1 Key Market Trends and Growth Factors
6.5.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.5.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.6 Prostate Cancer
6.6.1 Key Market Trends and Growth Factors
6.6.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.6.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.7 Liver Cancer
6.7.1 Key Market Trends and Growth Factors
6.7.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.7.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.8 Esophagus Cancer
6.8.1 Key Market Trends and Growth Factors
6.8.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.8.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.9 Cervical Cancer
6.9.1 Key Market Trends and Growth Factors
6.9.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.9.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.10 Kidney Cancer
6.10.1 Key Market Trends and Growth Factors
6.10.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.10.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.11 Bladder Cancer
6.11.1 Key Market Trends and Growth Factors
6.11.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.11.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
6.12 Others
6.12.1 Key Market Trends and Growth Factors
6.12.2 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
6.12.3 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
7. Cancer/Oncology Drug Market, By Region
7.1 Global Market Trends and Growth Factors
7.2 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.3 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.4 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.5 Market Size and Forecast, by Region, 2017-2032, (USD Billion)
7.6 North America
7.6.1 Key Market Trends and Growth Factors
7.6.2 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.6.3 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.6.4 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.6.5 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
7.6.6 U.S.
7.6.6.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.6.6.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.6.6.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.6.7 Canada
7.6.7.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.6.7.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.6.7.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.6.8 Mexico
7.6.8.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.6.8.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.6.8.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.7 Europe
7.7.1 Key Market Trends and Growth Factors
7.7.2 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.7.3 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.7.4 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.7.5 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
7.7.6 UK
7.7.6.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.7.6.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.7.6.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.7.7 Germany
7.7.7.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.7.7.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.7.7.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.7.8 France
7.7.8.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.7.8.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.7.8.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.7.9 Russia
7.7.9.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.7.9.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.7.9.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.7.10 Italy
7.7.10.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.7.10.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.7.10.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.7.11 Rest of Europe
7.7.11.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.7.11.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.7.11.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.8 Asia-Pacific
7.8.1 Key Market Trends and Growth Factors
7.8.2 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.8.3 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.8.4 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.8.5 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
7.8.6 China
7.8.6.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.8.6.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.8.6.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.8.7 India
7.8.7.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.8.7.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.8.7.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.8.8 Japan
7.8.8.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.8.8.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.8.8.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.8.9 Australia
7.8.9.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.8.9.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.8.9.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.8.10 Rest of Asia-Pacific
7.8.10.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.8.10.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.8.10.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.9 Latin America
7.9.1 Key Market Trends and Growth Factors
7.9.2 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.9.3 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.9.4 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.9.5 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
7.9.6 Brazil
7.9.6.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.9.6.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.9.6.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.9.7 Argentina
7.9.7.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.9.7.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.9.7.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.9.8 Mexico
7.9.8.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.9.8.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.9.8.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.9.9 Chile
7.9.9.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.9.9.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.9.9.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.10 Middle East and Africa
7.10.1 Key Market Trends and Growth Factors
7.10.2 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.10.3 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.10.4 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.10.5 Market Size and Forecast, by Country, 2017-2032, (USD Billion)
7.10.6 South Africa
7.10.6.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.10.6.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.10.6.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.10.7 UAE
7.10.7.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.10.7.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.10.7.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.10.8 Saudi Arabia
7.10.8.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.10.8.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.10.8.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
7.10.9 Israel
7.10.9.1 Market Size and Forecast, by Drug, 2017-2032, (USD Billion)
7.10.9.2 Market Size and Forecast, by Therapy, 2017-2032, (USD Billion)
7.10.9.3 Market Size and Forecast, by Cancer Type, 2017-2032, (USD Billion)
8. Competitive Benchmarking & Company Profiles
8.1 Competitive Benchmarking
8.1.1 Company Market Share
8.1.2 Product Mapping
8.1.3 Competitive Heat map
8.2 AbbVie Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Product Offering
8.2.4 Strategic Initiatives
8.2.5 SWOT
8.2.6 Ansoff Matrix
8.3 Amgen
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Product Offering
8.3.4 Strategic Initiatives
8.3.5 SWOT
8.3.6 Ansoff Matrix
8.4 Astellas Pharma Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Product Offering
8.4.4 Strategic Initiatives
8.4.5 SWOT
8.4.6 Ansoff Matrix
8.5 AstraZeneca PLC
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Product Offering
8.5.4 Strategic Initiatives
8.5.5 SWOT
8.5.6 Ansoff Matrix
8.6 Bristol-Myers Squibb Company
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Product Offering
8.6.4 Strategic Initiatives
8.6.5 SWOT
8.6.6 Ansoff Matrix
8.7 Hoffmann-La Roche Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Product Offering
8.7.4 Strategic Initiatives
8.7.5 SWOT
8.7.6 Ansoff Matrix
8.8 Johnson & Johnson (Janssen Global Services, LLC)
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Product Offering
8.8.4 Strategic Initiatives
8.8.5 SWOT
8.8.6 Ansoff Matrix
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Product Offering
8.9.4 Strategic Initiatives
8.9.5 SWOT
8.9.6 Ansoff Matrix
8.10 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Product Offering
8.10.4 Strategic Initiatives
8.10.5 SWOT
8.10.6 Ansoff Matrix
8.11 Pfizer Inc.
8.11.1 Company Overview
8.11.2 Financial Analysis
8.11.3 Product Offering
8.11.4 Strategic Initiatives
8.11.5 SWOT
8.11.6 Ansoff Matrix
9. Industry Connects and Seminars
